Dihydrotachysterol is a synthetic analog of vitamin D that does not require renal activation like vitamin D2 or Vitamin D3. A vitamin D that can be regarded as a reduction product of vitamin D2.
- Mechanism
- Curator reviewed
Once hydroxylated to 25-hydroxydihydrotachysterol, the modified drug binds to the vitamin D receptor. The bound form of the vitamin D receptor serves as a transcriptional regulator of bone matrix proteins, inducing the expression of osteocalcin and suppressing synthesis of type I collagen. Vitamin D (when bound to the vitamin D receptor)stimulates the expression of a number of proteins involved in transporting calcium from the lumen of the intestine, across the epithelial cells and into blood. This stimulates intestinal calcium absorption and increases renal phosphate excretion. These are functions that are normally carried out by the parathyroid hormone.
- Primary indication
- Used for the prevention and treatment of rickets or osteomalacia, and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism.Curator reviewed · 2 structured indications
- Formula / weight
- C28H46O · 398.6642 g/mol (avg)
- First approval
- Canada, 2001
- Also known as
- Anti-tetany substance 10
Resolves to
ILYCWAKSDCYMBB-OPCMSESCSA-NSMILESCC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1CWhat you can answer from here — as of September 20, 2026
Which drugs share a target with Dihydrotachysterol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account